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Abstract
Background: An increased prevalence of coeliac disease in patients with primary biliary cirrhosis
has been recently reported. However, in other studies the association has not been confirmed.
There have been no formal attempts to systematically evaluate patients with autoimmune
cholangitis for coeliac disease.
Methods: Sera from 62 patients with primary biliary cirrhosis, 17 with autoimmune cholangitis and
100 blood donors were screened for anti-gliadin, anti-endomysial, anti-reticulin, and IgA class
antibodies to guinea pig liver-derived tissue transglutaminase. Eighteen untreated coeliacs served
as methodological controls. Analyses were performed by using the χ 2 and Fischer's exact tests.
Results: Anti-gliadin antibodies were detected in 21% of patients with primary biliary cirrhosis,
35% of patients with autoimmune cholangitis, and 3% of controls (p < 0.001). IgA class gliadin
antibodies positivity was more pronounced in patients with Scheuer's stage III-IV disease (p < 0.05).
Anti-transglutaminase antibodies were detected in 10% and in 18% of patients with primary biliary
cirrhosis and autoimmune cholangitis respectively (p < 0.001). Anti-reticulin and anti-endomysial
antibodies were negative in all patients. Duodenal biopsies were performed in 59% and 71% of
patients with primary biliary cirrhosis and autoimmune cholangitis respectively, tested positive for
at least one antibody class. No histological features of coeliac disease were found.
Conclusions: We were unable to demonstrate an increased risk of coeliac disease in patients with
primary biliary cirrhosis and autoimmune cholangitis. Our results confirm the previously reported
high prevalence of false-positive anti-gliadin and guinea pig liver-derived anti-tissue transglutaminase
antibodies in patients with chronic liver disease.
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Background
Since the initial description of four patients with coeliac
disease (CD) and primary biliary cirrhosis (PBC) [1],
there have been several subsequent reports demonstrating
an association of these two diseases [2–7]. Recently, a
number of epidemiological studies reported an increased,
up to 7%, prevalence of CD in patients with PBC and an
increased prevalence, up to 3%, of PBC in patients with
CD [8,9]. Screening for one disease when the other is
identified has therefore been suggested. However, in other
studies this association was found less pronounced or has
not been confirmed [10–13]. Autoimmune cholangitis
(AIC) was first reported as an overlap syndrome of au-
toimmune hepatitis and PBC, but is considered by most
as a discrete entity of antimitochondrial antibody (AMA)-
negative PBC with autoimmune characters [14]. Apart
from a case report [15], no relation of adult CD to autoim-
mune cholangitis has so far been described. However,
there have been no formal attempts to systematically eval-
uate patients with AIC for CD, presumably because AIC
represents a rare form of chronic cholestatic liver disease.
Although a definite diagnosis of CD still requires his-
topathologic examination of the small intestinal mucosa,
the screening methods for large number of individuals are
based on non-invasive serological tests, namely, anti-glia-
din (AGA, IgG and IgA class), anti-reticulin (ARA R1-type,
IgA class) and anti-endomysial (EMA, IgA class) antibod-
ies [16–18]. The combined use of serum IgG-AGA (good
sensitivity) and IgA-EMA (good specificity) has resulted in
a reliable screening test for diagnosis of CD [19]. Howev-
er, anti-gliadin antibodies (AGAs) are not suitable for CD
screening in patients with chronic liver diseases including
PBC, as an unacceptably high percentage of false-positives
was reported in several studies [11,20,21]. In this respect,
a previous study revealed that the serum IgA-EMA assay is
the optimum test for predicting CD in patients with
chronic liver disease [11]. Although IgA class antibodies
to guinea pig liver-derived tissue transglutaminase (IgA-
tTG) have been shown to be highly specific and sensitive
for the diagnosis of CD [22–26], it was recently reported
that in patients with chronic liver disease there was a high
frequency of false-positives which disappeared when hu-
man tTG was used as the antigen in the ELISA system [27].
In the present study we evaluated AGAs, IgA-ARA, IgA-
EMA and guinea pig liver-derived IgA-tTG in 62 patients
with PBC and 17 patients with AIC. Intestinal biopsies
have been subsequently performed in the majority of pa-
tients tested positive for at least one antibody class.
Methods
Materials
Serum samples from 62 patients with PBC (53 women
and nine men; mean age, 59 years; range, 32–85 years)
and 17 patients with AIC (16 women and one man; mean
age, 62 years; range, 52–77 years) were used in the study.
The samples were collected prospectively over a 2 yr. peri-
od (1999–2000) and stored in aliquots at -20°C. Diagno-
sis of PBC was based on standard laboratory findings,
compatible liver histology and the presence of AMA in tit-
er > 1:80. Class 2 AMA antibodies (M2) detected by ELISA
were positive in all patients. According to Scheuer's classi-
fication [28], 34 patients (54%) had stage I-II and 28
(46%) stage III-IV disease. The mean follow-up period
from the time of diagnosis was 5.2 years (range, 1–9.4
years).
The diagnosis of AIC has been made on cholestatic pa-
tients with a liver biopsy compatible with PBC, without
AMA or M2 positivity. ANA were positive (titers ≥  1:160)
in all 17 patients. Anti-smooth muscle antibodies were
positive (titer ≥  1:80) in 9 patients. According to Scheuer's
classification, 10 patients (58%) had stage I-II and 7
(42%) stage III-IV disease. The mean follow-up after diag-
nosis was 6.6 years (range, 1–7.8 years).
Ultrasound, computed tomography and endoscopic retro-
grade cholangiography ruled out the possibility of biliary
obstruction, when the latter was suspected. No patient
had a family history of CD, or IgA deficiency. One PBC pa-
tient was HbsAg positive and one PBC patient and two
AIC patients were anti-HCV positive. One hundred Cretan
adults selected at random from blood donors served as
controls. Eighteen serum samples from symptomatic, bi-
opsy-proven, AMA negative adults with CD were included
in the study as methodological controls. Total IgA was
measured in all CD patients and healthy controls to ex-
clude IgA deficiency.
Methods
Two operators unaware of the clinical parameters per-
formed the immunological tests. All PBC, AIC, CD and
control sera were screened for AGAs, IgA-ARA, IgA-EMA
and IgA-tTG. IgA- and IgG-AGA were screened by a com-
mercial ELISA at a dilution of 1:50 (Alphadia SA/NV, Bel-
g i u m ) .  V a l u e s  g r e a t e r  t h a n  5 0  U / m L  w e r e  c o n s i d e r e d
positive. Results were considered doubtful and repeated
for values between 45 and 50 U/mL. For IgA-ARA R1-type,
sera were tested by an indirect immunofluorescence (IIF)
test at a 1:10 and 1:40 dilution, using rat liver, kidney and
stomach as substrates (Sanofi Diagnostics Pasteur,
France). Sera were screened for IgA-EMA by IIF, using both
monkey oesophagus (Biosystems, Barcelona, Spain) and
human umbilical cord (Eurospital SpA, Trieste, Italy) as
substrates. Titers of ≥  1:5 were considered positive. To
avoid false-negative results, IgA-EMA were also evaluated
at a 1:50 dilution. IgA-tTG were tested by a commercially
available guinea-pig liver-derived tTG ELISA kit at a dilu-
tion of 1:101, according to manufacturers' instructions
(QUANTA Lite™ tTG ELISA, INOVA Diagnostics, San Di-BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/5
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ego, USA). The samples were classified as negative (<20
Units), weakly positive (20–30 Units) and strongly posi-
tive (>30 Units). Small intestinal biopsies were performed
at endoscopy using endoscopic forceps. Four biopsy spec-
imens from opposite sites of the distal duodenum were
obtained and evaluated by one observer specialized in
gastrointestinal tract pathology with regard to the villi/
crypts ratio and the number of intraepithelial lym-
phocytes (IELs) per 100 surface epithelial cells. Small
bowel biopsies from the patients with PBC and AIC were
evaluated blindly with those obtained from the 18 pa-
tients with untreated CD. When biopsy specimen revealed
features of CD [29], namely, a lowering of the villous
height to crypt depth ratio (normal, 3–5:1) and/or an in-
crease in IELs (normal, 10–30 per 100 epithelial cells) a
more detailed histological classification was applied [30].
Test results were compared using a 2 ×  2 contingency table
and chi-squared statistics. When appropriate, Fisher's ex-
act test was used. P values below 0.05 were considered sig-
nificant.
Results
IgA class anti-gliadin antibodies and IgA class antibodies
to tissue transglutaminase were detected with a signifi-
cantly increased frequency in patients with both PBC and
AIC as compared to healthy blood donors (Table 1). In
contrast, none of the PBC and AIC patients was tested pos-
itive for anti-reticulin or anti-endomysial antibodies.
Controls were tested negative for anti-reticulin, anti-en-
domysial and IgA class anti-tissue transglutaminase anti-
bodies.
PBC patients (Table 2)
Both anti-gliadin antibodies were detected in 13 out of 62
patients with PBC (21% vs. 3% in controls, p < 0.001).
IgA-AGA were tested positive in 12 patients (19%, p <
0.001), of whom 5 had stage I-II disease, and 7 had stage
II-IV disease. IgA-AGA positivity was significantly more
pronounced in patients with stage III-IV disease (25% vs
14%, p < 0.05). IgA-tTG were detected in 6 patients
(10%), 3 of whom had stage I-II disease and another 3
stage III-IV disease, while tested negative in all controls (p
< 0.001). Serology was negative in the two patients with a
superimposed viral hepatitis infection.
AIC patients (Table 3)
IgA-AGA were tested positive in 6 patients with AIC (35%
vs. 3% in controls, p < 0.001), two with stage I-II disease
and four with stage III-IV disease. IgA-AGA positivity was
significantly more pronounced in patients with stage III-
IV disease (57% vs 20%, p < 0.05). IgA-tTG were detected
in 3 patients with AIC (18%), two patients with stage I-II
disease and one patient with stage III-IV disease, while
tested negative in all controls (p < 0.001). Serology was
negative in two AIC patients with superimposed hepatitis
C.
CD patients
All 18 patients with coeliac disease were tested positive for
IgA-ARA, IgA-EMA and IgA-tTG, whereas 16 of them had
also both IgA and IgG anti-gliadin antibodies.
Healthy blood donors
None of the 100 tested sera were found to be IgA-EMA or
IgA-tTG positive. However AGAs were present in 3 indi-
viduals (IgA-AGA in one and IgG-AGA in two).
Table 1: Prevalence (%) of antibodies in patients and in controls
PBC n = 62 (%) AIC n = 17(%) BD n = 100 CD n = 18
IgA-AGA 12(19)* 6 (35)* 11 8
IgG-AGA 3(5) - 2 16
Any AGA 13 (21)* 6 (35)* 31 8
Both AGAs 2(3) - 1 16
IgA-ARA -- - 1 8
IgA-EMA -- - 1 8
IgA-tTG 6(10)* 3(18)* -1 8
IgA-tTG and AGAs 2(3) 2 (12)* -1 8
n = number of patients; * = where p less than 0.05, PBC = primary biliary cirrhosis; AIC = autoimmune cholangitis; CD = coeliac disease; BD = 
blood donors; IgA-AGA = anti-gliadin antibodies, IgA class; IgG-AGA = anti-gliadin antibodies, IgG class; AGAs = anti-gliadin antibodies; IgA-ARA = 
IgA class anti-reticulin antibodies, RI type; IgA-EMA = anti-endomysial antibodies, IgA class; IgA-tTG = antibodies to tissue transglutaminase, IgA 
classBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/5
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Duodenal biopsies
Overall, biopsies were performed in 10 out of 17 PBC pa-
tients (59%) and 5 out of 7 AIC patients (71%) tested IgA-
AGA and/or IgG-AGA and/or IgA-tTG positive. Five pa-
tients died shortly after testing positive and four patients
refused any further investigation. None of the biopsied
PBC and AIC patients had features suggestive of CD. Small
bowel biopsies of our 18 patients with CD revealed partial
villous atrophy (Marsh IIIa) in three, subtotal villous atro-
phy (Marsh IIIb) in eleven and total villous atrophy
(Marsh IIIc) in four.
Discussion
In contrast to recent reports from Wales [8], Scandinavia
[9], Northern Ireland [31], and Canada [32], the present
study has not been able to demonstrate an increased risk
of coeliac disease in this group of 62 Cretan patients with
primary biliary cirrhosis. Our results are consistent with
data from Sweden [11] and Italy [12,13], suggesting that
if there is no clinical suspicion of CD, screening with anti-
endomysial antibodies should not be performed routine-
ly in all patients with PBC.
A possible explanation relevant to these controversies
could be the methodological differences in detecting and
defining CD, like the different serological tests used for
Table 2: Antibody titers and intestinal biopsies in patients with primary biliary cirrhosis
Patient Disease stagea
IgA-AGA IgG-AGA IgA-ARA IgA-EMA IgA-tTG Intestinal biopsy
1. I-II - - - - 49 Normal
2. I-II 199 58,6 - - 50 Normal
3. I-II - - - - 25 Normal
4. I-II 55 - - - - ND
5. I-II 166 - - - - Normal
6. I-II 200 200 - - - Normal
7. I-II 70 - - - - ND
8. III-IV 244 - - - - ND
9. III-IV 144 - - - - ND
10. III-IV - 67,4 - - - ND
11. III-IV - - - - 21 ND
12. III-IV 106 - - - 32 Normal
13. III-IV - - - - 28 Normal
14. III-IV 97 - - - - Normal
15. III-IV 53 - - - - Normal
16. III-IV 57 - - - - Normal
17. III-IV 253 - - - - ND
aAccording to Scheuer's classification; ND = not done









1. I-II 157 - - - 21,9 Normal
2. I-II - - - - 26 Normal
3. I-II 153 - - - - ND
4. III-IV 55,9 - - - - ND
5. III-IV 382 - - - 32 Normal
6. III-IV 65 - - - - Normal
7. III-IV 60 - - - - Normal
aAccording to Scheuer's classification; ND = not doneBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/5
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screening (AGAs and/or IgA-EMA), the degree of intestinal
damage, or the spectrum of clinical presentation of CD in
patients studied. Patients with malabsorption, diarrhoea,
weight loss, and total villous atrophy represent perhaps
only 30–40% of the entire spectrum of gluten-sensitised
individuals [19]. However, studies supporting the associ-
ation between PBC and CD have included mainly symp-
tomatic or complicated cases. In Kingham's et al study [8],
CD in patients with PBC was sought by investigating fea-
tures suggestive of malabsorption, a family history of CD,
the presence of AGAs, or the finding of otherwise unex-
plained haematinic deficiency. In Sorensen's et al paper
[9], it is not clear whether all patients with CD were sys-
tematically evaluated for PBC. PBC was found in patients
hospitalised for CD, which presumably excluded patients
with subclinical or silent disease. Furthermore, no infor-
mation was available for patients treated as outpatients.
The inconsistencies between studies may also be attribut-
ed to the ethnic variability of CD prevalence in the differ-
ent populations. The prevalence of CD in Greece is
currently unknown, because of the lack of official epide-
miological data, but it is probably low. A crude estimation
concerning of the prevalence of CD in Greece is provided
from an endoscopic study from Athens, reporting one
new case of unsuspected CD per 520 endoscopies [33].
When we retrospectively looked for, only 23 adult pa-
tients with symptomatic gluten-sensitive enteropathy
were found over a 9 year period in a specialized University
Unit, which is the main reference center for the total pop-
ulation of the island of Crete (approximately 500 000
people).
We do recognize the fact that the size of the studied sam-
ples is not large enough to permit us to refute the presence
of an association between CD and PBC safely. However,
our inability to confirm this association is in agreement
with recent data from large Italian series [13], consisted of
336 patients with CD and 65 cases with PBC. In this study,
which can be assumed to be representative of the Mediter-
ranean population, only one case of PBC among patients
with CD was identified and no case of CD in the group of
PBC.
Patients with autoimmune cholangitis were not included
in the studies aiming to estimate the risk of CD in patients
with PBC. In our small series, no case of CD was found
among the 17 patients with autoimmune cholangitis and
thus an association could not be established.
A possible limitation of our study may be the relatively
low percentage of duodenal biopsies performed in pa-
tients with primary biliary cirrhosis tested positive for at
least one antibody class. However, this was also the case
in studies supporting the association. Our patients were
screened for IgA-EMA by indirect immunofluorescence
(IIF) test, using both monkey esophagus and human um-
bilical cord as substrates which have been shown to be
highly sensitive and specific indicators of untreated coeli-
ac disease [16,17]. Thus missing a case of CD in our pa-
tients with PBC seems rather unlikely. It was previously
reported that the development of IgA-EMA depends on
the severity of intestinal histopathology of CD and a sub-
group of asymptomatic coeliacs negative for AGAs or IgA-
EMA will be under-diagnosed, especially those with mi-
nor tissue damage [30]. However, none of the studies sup-
porting or failing to demonstrate the association have
focused on this aspect.
In our series, 21% of PBC and 35% of AIC patients were
tested positive for AGAs. Furthermore, IgA-AGA positivity
was significantly more pronounced in patients with
Scheuer's stage III-IV disease. Floreani et al [20] reported
that IgA-AGA were found in 3.4%, whereas both IgA and
IgG-AGA in 6.8% of PBC patients. Likewise, Sjoberg et al
[11] reported that the occurrence of false-positive AGAs in
PBC patients was as high as 16%. We therefore believe, as
previously suggested [11,20,21], that the presence of
AGAs in PBC and AIC seems to be secondary to liver dam-
age per se and represent a marker of non-specific immune
reactivity. Finally, our results confirm the previously re-
ported low specificity of guinea pig liver-derived tTG ELI-
SA in patients with chronic liver disease [27]. We were
unable to compare our results with those obtained by a
human recombinant tTG ELISA as the latter is not current-
ly commercially available in our country.
Conclusions
We confirmed the previously reported high prevalence of
false-positive anti-gliadin and guinea pig liver-derived
anti-tissue transglutaminase antibodies in patients with
chronic liver disease. We were unable to confirm observa-
tions suggesting an over-representation of coeliac disease
in patients with primary biliary cirrhosis. Our findings
support the idea that in areas of low prevalence of CD, in
the absence of clinical suspicion, screening all patients
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